Item 5.07 Submission of Matters to a Vote of Security Holders.
Set forth below are the voting results for the three proposals considered and
voted upon at the 2021 Annual Meeting, all of which were described in
ApolloMed's definitive proxy statement for the 2021 Annual Meeting, filed with
the
Proposal 1. Election of Directors
ApolloMed's stockholders elected, by the votes indicated below, eleven persons to serve as directors of ApolloMed until its 2022 Annual Meeting of Stockholders and until their successors are duly elected and qualify. The following sets forth the results of the voting with respect to each candidate:
Director For Withheld Broker Non-Votes (1) Kenneth Sim, M.D. 35,332,152 204,028 4,903,071 Thomas S. Lam, M.D., M.P.H. 35,341,388 194,792 4,903,071 Mitchell W. Kitayama 31,704,446 3,831,734 4,903,071 David G. Schmidt 33,212,720 2,323,460 4,903,071 Mark Fawcett 33,730,120 1,806,060 4,903,071 Michael F. Eng 35,267,667 268,513 4,903,071 Li Yu 35,267,387 268,793 4,903,071 Ernest A. Bates, M.D. 33,400,743 2,135,437 4,903,071 Linda Marsh 35,210,109 326,071 4,903,071 John Chiang 33,679,987 1,856,193 4,903,071 Matthew Mazdyasni 35,017,037 519,143 4,903,071
(1) Broker non-votes represent proxies that are uninstructed on a proposal and submitted by brokers or other nominees who lack discretionary authority to vote on the proposal absent instructions from the beneficial owner of shares of stock.
Based on these voting results, each of the eleven nominees for director were elected to serve until ApolloMed's 2022 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified.
Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm
ApolloMed's stockholders voted to ratify the appointment of
Based on these voting results, the stockholders ratified the appointment of
--------------------------------------------------------------------------------
Proposal 3. Approval of the Amendment of the Company's 2015 Equity Incentive Plan
ApolloMed's stockholders voted to approve the amendment of the Company's 2015 Equity Incentive Plan to increase the maximum number of shares authorized for issuance thereunder by 2,000,000 shares, from 1,500,000 shares to 3,500,000 shares. 27,368,444 votes were cast "for" the approval, 7,816,984 votes were cast "against" the approval, 350,752 votes abstained and 4,903,071 broker non-votes for this proposal.
Based on these voting results, the stockholders approved the amendment of the Company's 2015 Equity Incentive Plan to increase the maximum number of shares authorized for issuance thereunder by 2,000,000 shares, from 1,500,000 shares to 3,500,000 shares.
--------------------------------------------------------------------------------
© Edgar Online, source